TORONTO, Jan. 21, 2015 /CNW/ - Bedrocan Cannabis Corp. (TSXV: BED) (the "Company") wishes to announce today that it has granted an aggregate of 1,375,000 stock options to directors, officers, employees and consultants of the Company, each such stock option entitling the holders thereof to acquire one common share of the Company at an exercise price of $0.73 for a period of five years. The stock options vest over a period of three years with one third vesting on the first anniversary date of the grant and the remaining stock options vesting evenly on a quarterly basis over the second and third year of the grant.
Bedrocan and Bedrocan BV are focused on medicinal cannabis research and product innovation, and have been producing and supplying government-regulated medicinal cannabis for 13 years. Bedrocan's strains of pharmaceutical-grade cannabis have been used by more than 20,000 patients in seven countries, including Canada. The Company is committed to clinical research with ISO 9001-rated production processes and product development, on an international scale. Bedrocan is one of only two companies currently supplying pharmaceutical-grade medicinal cannabis in Canada. Bedrocan Cannabis Corp. trades on the TSX Venture Exchange under the symbol "BED". www.bedrocan.ca
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Bedrocan Cannabis Corp.
For further information: Cam Battley, Bedrocan Cannabis Corp., [email protected], +1.905.864.5525, www.bedrocan.ca; Investor relations: Jennifer Wood, TMX Equicom, [email protected], +1.416.815.0700, ext. 226